What this means
This is a plan for a study that has not started yet, and no results exist. It will test whether the two treatments change melasma and cause different side effects.
Plain-English summary written by an AI model from the registry listing.
- Status
- Opening soon
- Who can join
- Ages 35–55 · 82 women aged 35 to 55 in a hospital in Pakistan
- Where
- 1 site
The science
- Registered title
- Comparative Evaluation of Topical 30% Metformin and Kligman's Regimen in Women With Melasma
- Trial ID
- NCT07485777 ↗
- Phase
- Not applicable
- Study type
- interventional
- Conditions
- Melasma (Facial Melasma), Melasma
- What is tested
- Topical 30% metformin cream, Kligman's Regimen
- Sponsor
- Foundation University Islamabad
- Ages
- 35 Years to 55 Years
- Dates
- First posted Mar 20, 2026 · updated Mar 20, 2026
Registry summary
It's a prospective, randomised, assessor-blinded clinical study comparing topical 30% metformin with Kligman's regimen for melasma in women aged 35-55 years at Fauji Foundation Hospital, Rawalpindi. The study seeks to ascertain which treatment yields a more significant decrease in the modified MASI score over an 8-week period and which treatment is associated with fewer adverse effects, such as erythema, burning, peeling, and post-inflammatory hyperpigmentation. A total of 82 participants will be enrolled and randomly assigned to either metformin cream or Kligman's regimen, with both groups also using sunscreen. Assessments will be done at baseline, week 4, and week 8 through mMASI scoring, photographs, and side-effect monitoring. Data will be analyzed in SPSS 26 using t-tests and chi-square testing. The study is based on evidence suggesting metformin may offer comparable efficacy with better tolerability.
Sites (1)
- Fauji Foundation Hospital, Rawalpindi, Rawalpindi, Punjab Province, Pakistan